additional

OptimizeRx Corporation Announces Plan for Additional Board of Directors RefreshmentOptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment

OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment

April 18, 2025 16:15 ET  | Source: OptimizeRx Corporation WALTHAM, Mass., April 18, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the…

2 weeks ago
Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per ShareHeng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share

Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share

BOSTON, April 10, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Partners, LLC sent a letter on…

3 weeks ago
MSMEs Cannot Afford Additional INR 1.5 Lakhs per year as Cost of Compliance due to IMS: India SME ForumMSMEs Cannot Afford Additional INR 1.5 Lakhs per year as Cost of Compliance due to IMS: India SME Forum

MSMEs Cannot Afford Additional INR 1.5 Lakhs per year as Cost of Compliance due to IMS: India SME Forum

NEW DELHI, April 1, 2025 /PRNewswire/ -- The India SME Forum (ISF), the country's largest non-governmental organization for small and medium…

1 month ago
MEDIROM Mother Labs Executive Makes Additional Investment in Mother Labs Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of March 13, 2025, Approximately US$60 Million)MEDIROM Mother Labs Executive Makes Additional Investment in Mother Labs Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of March 13, 2025, Approximately US$60 Million)

MEDIROM Mother Labs Executive Makes Additional Investment in Mother Labs Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of March 13, 2025, Approximately US$60 Million)

TOKYO, March 13, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that Yasuhiro…

2 months ago
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO ConferenceIO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

February 23, 2025 12:07 ET  | Source: IO Biotech • Findings support the development of a novel peptide vaccine targeting…

2 months ago
Intelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares of Common StockIntelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares of Common Stock

Intelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares of Common Stock

February 21, 2025 16:05 ET  | Source: Intelligent Bio Solutions, Inc. NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intelligent…

2 months ago
Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional SharesBeta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares

Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares

January 31, 2025 17:56 ET  | Source: Beta Bionics, Inc. IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics,…

3 months ago
Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer ChemotherapiesSilexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA…

4 months ago
Senti Bio Announces Additional $11.5 Million of FinancingSenti Bio Announces Additional $11.5 Million of Financing

Senti Bio Announces Additional $11.5 Million of Financing

– Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced…

4 months ago
Senti Bio Announces Additional $11.5 Million of FinancingSenti Bio Announces Additional $11.5 Million of Financing

Senti Bio Announces Additional $11.5 Million of Financing

– Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced…

4 months ago